Phase I Trial of Lupus Oral Inhibitor Meets Safety, Tolerability Targets
Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D subsidiary Hutchison MediPharma (HMP) has completed its Phase I study of HMPL-523, a potential global first-in-class oral inhibitor targeting the spleen tyrosine kinase Syk, a key protein involved in B-cell signaling. Modulation of the B-cell signaling pathway has proven to significantly advance…